A Rare B-Myeloid Conversion of Follicular Lymphoma into Clonally Related Acute Myeloid Leukemia: A Case Report
暂无分享,去创建一个
[1] A. Hui,et al. Role of Biomarkers in FLT3 AML , 2022, Cancers.
[2] Hongtao Liu. Emerging agents and regimens for AML , 2021, Journal of Hematology & Oncology.
[3] A. López-Guillermo,et al. Follicular lymphoma , 2019, Nature Reviews Disease Primers.
[4] C. Jordan. Can we selectively target AML stem cells? , 2019, Best practice & research. Clinical haematology.
[5] A. Feldman,et al. Coactivation of NF-κB and Notch signaling is sufficient to induce B cell transformation and enables B-myeloid conversion. , 2019, Blood.
[6] Xiaomei Ma,et al. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. , 2019, Blood reviews.
[7] G. Salles,et al. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. , 2019, Blood.
[8] P. Barr,et al. How I treat early-relapsing follicular lymphoma. , 2019, Blood.
[9] A. Wei,et al. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] L. Medeiros,et al. Acute myeloid leukemia with t(8;16)(p11.2;p13.3)/KAT6A-CREBBP in adults , 2019, Annals of Hematology.
[11] Michael R. Green,et al. Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphoma , 2019, bioRxiv.
[12] Anxun Wang,et al. Up-regulation of INSR/IGF1R by C-myc promotes TSCC tumorigenesis and metastasis through the NF-κB pathway. , 2018, Biochimica et biophysica acta. Molecular basis of disease.
[13] A. Letai,et al. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study. , 2018, The Lancet. Oncology.
[14] B. Darbro,et al. Leukemic Transdifferentiation of Follicular Lymphoma Into an Acute Histiocytic Leukemia in a 52-Year-Old Caucasian Woman , 2016, Laboratory medicine.
[15] Michael R Green,et al. miR-146a promotes the initiation and progression of melanoma by activating Notch signaling , 2014, eLife.
[16] Denis Thieffry,et al. C/EBPα poises B cells for rapid reprogramming into induced pluripotent stem cells , 2013, Nature.
[17] T. Graf,et al. Stepwise Reprogramming of B Cells into Macrophages , 2004, Cell.